Embed Size (px)
Citation preview
<br /><br />E1308:<br />A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Disclosures
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Slide 3
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Background: HPV+ OP SCCa
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Rationale: Cetuximab based Induction CT
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Slide 6
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Endpoints
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Statistics
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Results
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Slide 10
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Results: Acute Toxicity
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Late Toxicity
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Response: Induction
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Response: Following Cetux/IMRT
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Endpoint: 2yr PFS and OS
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
PFS and Survival: Dose
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Low Dose: T stage and N stage
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Smoking: PFS and Survival
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Best Outcome: <T4, T1-N2b, <10 pk-yr
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
First Failure Patterns: Low-dose pts
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Summary
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Conclusions
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Designed and conducted by:
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
